ShareValue scores for 300204.SHE: Valuation 36, Quality 30, Growth 31, Health 39.

300204.SHE
SZSE

Staidson Beijing Biopharma

CN¥24.58(+2.85%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

-11% to 10%
Valuation
36
Overvalued
Price vs Value
Quality
30
Weak
Business Strength
Growth
31
Weak
Revenue & Earnings
Health
39
Stressed
Financial Stability
Momentum
32
Bearish
Price Trend

Company Details

About

Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research, development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. It also provides treatments for respiratory and critical care illnesses, and neurological disorders. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyethylene Glycol Electrolyte Powder (IV), Aspirin enteric-coated tablets, Compound polyethylene glycol (3350) electrolyte oral solution, Compound polyethylene glycol (3350) electrolyte vitamin C powder. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China. Address: No. 36, Jingha 2nd Road, Beijing, China, 100176

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026